Article
Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.
Blood advances - 8 Dec 2020
Tremblay Douglas, Mesa Ruben, Scott Bart, Buckley Sarah, Roman-Torres Karisse, Verstovsek Srdan, Mascarenhas John
Abstract excerpt
Myelofibrosis (MF) has heterogeneous clinical manifestations, with some patients exhibiting a myelodepletive phenotype characterized by cytopenias and an absent or low JAK2V617F allele burden. Ruxolitinib may be less effective in these patients. We assessed the efficacy of pacritinib, a JAK2/IRAK1 inhibitor, in MF patients with low JAK2V617F allele burden. In this post hoc analysis of the PERSIST-1 and -2 trials,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.